Malin Corporation
Investment company supporting innovative life sciences firms.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €303m Valuation: €324m | IPO | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (7 %) | (8 %) | 17 % | - | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (45 %) | (15 %) | 5 % | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (121 %) | (15 %) | 214 % | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 8 % | 16 % | - | - | - | - |
Source: Company filings or news article
Related Content
Malin Corporation PLC is a publicly traded investment firm headquartered in Dublin, Ireland, that provides long-term capital and strategic support to companies in the life sciences sector. Founded in 2015, the company invests in businesses developing innovative science and technology with the goal of delivering transformative results for patients and creating value for shareholders. Malin's investment focus includes oncology, immunology, and genetic diseases.
The company's business model is centered on acquiring and holding significant stakes in a concentrated portfolio of private and public life sciences companies. Its purpose is to create shareholder value by applying capital and strategic guidance to help its investee companies achieve their potential. The company has been listed on the Euronext Growth Market in Dublin since its inception. A notable aspect of Malin's strategy involves periodic capital returns to shareholders, often facilitated through tender offers and share buybacks following the successful exit from an investment. In early 2025, for example, the company completed a significant €150 million share buyback, cancelling approximately 77% of its issued share capital at the time.
The firm's leadership team, led by CEO Fiona Dunlevy, possesses expertise across life sciences, finance, and venture capital. Major shareholders include institutional investors and hedge funds, such as Pentwater Capital Management LP and the Ireland Strategic Investment Fund. In recent years, Malin has been undergoing a strategic winding down, monetizing its assets and returning substantial capital to its investors, marking a significant turnaround from its initial public offering price in 2015.
Keywords: life sciences investment, venture capital, strategic capital, patient outcomes, shareholder value, oncology, immunology, biopharmaceutical, medical technology, drug discovery, clinical-stage companies, Euronext Dublin, portfolio management, asset monetization, share buyback, capital returns, healthcare investing, innovative therapies, Ireland Strategic Investment Fund, Pentwater Capital Management
Tech stack
